DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,850.00
+5.00 (0.13%)
At close: Aug 3, 2026

DongKoo Bio & Pharma Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
22,73721,56125,37215,71312,51419,557
Short-Term Investments
1,1241,107506.91,9411,351143.14
Trading Asset Securities
17,42612,49710,3715,24521,27112,399
Cash & Short-Term Investments
41,28735,16536,25022,89835,13632,100
Cash Growth
4.13%-3.00%58.31%-34.83%9.46%8.50%
Accounts Receivable
22,70919,34319,87619,87918,50315,774
Other Receivables
559.49253.081,3521,570898.47633.49
Receivables
26,10421,37023,95322,44919,40216,408
Inventory
43,74949,99645,96242,60631,42824,964
Prepaid Expenses
746.4450.63324.71216.61225.89229.66
Other Current Assets
857.7219,320751.62195.021,226131.5
Total Current Assets
112,744126,301107,24288,36587,41773,832
Property, Plant & Equipment
77,01177,44566,22250,48339,68140,051
Long-Term Investments
138,926121,47650,41939,80033,61935,498
Other Intangible Assets
8,3975,3865,46710,9039,0103,048
Long-Term Deferred Tax Assets
--3,162291.56.95-
Long-Term Deferred Charges
-2,9377,705---
Other Long-Term Assets
2,4642,8053,8431,2602,3252,358
Total Assets
339,542336,350244,061191,103172,059154,786

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
7,3985,29115,59111,20214,30011,591
Accrued Expenses
10,4749,92011,33710,2749,6376,496
Short-Term Debt
95,205105,15674,87640,50033,00018,070
Current Portion of Long-Term Debt
9,653----5,000
Current Portion of Leases
626.13639.78681.03842.63567.83453.23
Current Income Taxes Payable
4,361390.963,3251,6382,5761,978
Other Current Liabilities
19,61716,0769,4418,8635,9636,434
Total Current Liabilities
147,334137,473115,25173,31866,04450,022
Long-Term Debt
22,27922,85210,4671,447--
Long-Term Leases
344.08134.07616.951,014754.22770.27
Pension & Post-Retirement Benefits
-00277.090205.81
Long-Term Deferred Tax Liabilities
2,6936,7778.894.5140.932,315
Other Long-Term Liabilities
18,29016,95412,2694,5963,0151,350
Total Liabilities
190,940184,190138,61380,65869,95354,662

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
14,23214,23214,23214,23214,23214,232
Additional Paid-In Capital
33,51633,55533,06333,06333,06333,063
Retained Earnings
110,239114,06167,32069,73561,67557,158
Treasury Stock
-10,545-10,545-10,545-7,137-7,058-4,062
Comprehensive Income & Other
635.88398.211,261507.18193.39-266.18
Total Common Equity
148,078151,702105,332110,400102,106100,124
Minority Interest
523.82456.9116.0344.92--
Shareholders' Equity
148,602152,159105,448110,445102,106100,124
Total Liabilities & Equity
339,542336,350244,061191,103172,059154,786

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
128,107128,78286,64143,80434,32224,294
Net Cash (Debt)
-86,820-93,617-50,391-20,906813.887,806
Net Cash Growth
-----89.57%33.61%
Net Cash Per Share
-3044.02-3329.90-1856.67-756.8929.32276.23
Filing Date Shares Outstanding
27.0427.0427.0427.6127.6228.04
Total Common Shares Outstanding
27.0427.0427.0427.6127.6228.04
Working Capital
-34,590-11,173-8,00915,04621,37423,811
Book Value Per Share
5475.845609.853895.103998.843696.333570.78
Tangible Book Value
139,681146,31799,86599,49793,09697,076
Tangible Book Value Per Share
5165.315410.703692.933603.923370.163462.08
Land
13,26213,26213,26210,84910,84910,584
Buildings
28,43028,81527,61329,66727,35326,899
Machinery
9,0029,52012,45619,76817,74117,813
Construction In Progress
21,67721,2837,82310,6941,451887.9